These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15167152)

  • 1. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility and cost-benefit analyses: how did we get here and where are we going?
    Moayyedi P; Mason J
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):527-34. PubMed ID: 15167153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf.
    Siverskog J; Henriksson M
    Med Decis Making; 2020 Apr; 40(3):399-403. PubMed ID: 32172657
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic foundations of cost-effectiveness analysis.
    Garber AM; Phelps CE
    J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complaint-Directed Mini-Interventions for Depressive Symptoms: A Health Economic Evaluation of Unguided Web-Based Self-Help Interventions Based on a Randomized Controlled Trial.
    Wijnen BF; Lokman S; Leone S; Evers SM; Smit F
    J Med Internet Res; 2018 Oct; 20(10):e10455. PubMed ID: 30274958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of average cost-effective ratios.
    Laska EM; Meisner M; Siegel C
    Health Econ; 1997; 6(5):497-504. PubMed ID: 9353650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
    Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
    Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis.
    Frederix I; Hansen D; Coninx K; Vandervoort P; Vandijck D; Hens N; Van Craenenbroeck E; Van Driessche N; Dendale P
    Eur J Prev Cardiol; 2016 May; 23(7):674-82. PubMed ID: 26289723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the estimation of cost-effectiveness ratios.
    Johannesson M
    Health Policy; 1995 Mar; 31(3):225-9. PubMed ID: 10142618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis.
    Robinson R
    BMJ; 1993 Oct; 307(6908):859-62. PubMed ID: 8401133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allocating health care resources when people are risk averse with respect to life time.
    Hoel M
    Health Econ; 2003 Jul; 12(7):601-8. PubMed ID: 12825211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.
    Bridges JF; Onukwugha E; Mullins CD
    Pharmacoeconomics; 2010; 28(3):175-84. PubMed ID: 20067332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of medical records and patient questionnaires as sources for the estimation of costs within research studies and the implications for economic evaluation.
    Gillespie P; O'Shea E; Smith SM; Cupples ME; Murphy AW
    Fam Pract; 2016 Dec; 33(6):733-739. PubMed ID: 27587565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.